Sun Min Lim, MD, PhD, works in the Division of Medical Oncology in the Department of Internal Medicine at Yonsei University College of Medicine in Seoul, South Korea.
PALOMA-2 Reinforces Efficacy of SubQ Amivantamab in EGFR-Mutated NSCLC: Sun Lim Min, MD, PhD
September 9th 2025Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.